Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP: Atorvastatin Pleiotropic Effects
NCT00163202Phase 4Completed
- Sponsor
- Viatris
- Start
- Jun 2002
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of atorvastatin in coronary artery disease (CAD) and hypercholesterolemia (2 arms), sponsored by Viatris. Primary endpoint: Percentage change in high-sensitivity C-reactive protein at 26 weeks. Started Jun 2002; status: completed.
02
Drugs
atorvastatin
03
Conditions
coronary artery disease (CAD)hypercholesterolemia
Beyond the preview
Go deeper on NCT00163202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163202.